ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

leniolisib

Also written as “Leniolisib” and “CDZ173”.

Its studies are mostly in Common Variable Immunodeficiency · Primary Immunodeficiency Diseases · Lymphadenopathy, led by 2 companies.

Drug pageLeniolisib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 4, 20169 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Groupits history only74 open or runningphase 3since Aug 4, 2016Aug 4, 2016Nov 30, 2026phase 3 · NCT05438407
Novartis20 open or runningphase 3since Feb 24, 2015Feb 24, 2015none ahead

Also a collaborator on its studies: Aixial Group, CMIC Co, Ltd. Japan, Fortrea, Laboratory Corporation of America and Axial Biotech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2015First study: phase 3 study in Common Variable ImmunodeficiencyFirst studyNCT02435173 · 37 enrolled · United States, Belarus, Czechia and more
  2. Dec 9, 2015Named leniolisibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, CDZ173
  3. May 16, 2016Phase 2 study in Primary Sjögren's SyndromeNCT02775916 · 30 enrolled · Germany, Hungary

TargetBeta

PIK3CD →read by rule
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
idelalisibruleGilead Sciencesphase 428
duvelisibruleSecuraBiophase 326
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

All 2 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02775916Primary Sjögren's Syndrome · Germany, Hungary2CompletedMay 17, 201730
NCT02435173Common Variable Immunodeficiency · United States, Belarus, Czechia and more3CompletedAug 16, 202137

How it is read

Names in the registry

  • “Leniolisib”, 6 entries
  • “CDZ173”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.